Gedeon Richter and Pantarhei signed a license and supply agreement for commercialisation of a novel combined oral contraceptive

Gedeon Richter Plc. and Pantarhei Bioscience BV today announced that they have entered into a license and supply agreement to commercialise Pantarhei’s combined oral contraceptive (COC), containing 30 µg ethinyl estradiol, 150 µg levonorgestrel and 50 mg dehydroepiandrosterone (DHEA). The product is under development with successfully completed Phase II trials and is ready for further clinical studies to obtain marketing approval. The geographic scope of the agreement covers Europe, Russia, Latin America and Australia.

Read more: Press Release GedeonRichter – Pantarhei February 4, 2019

Gedeon Richter en Pantarhei ondertekenen een licentieovereenkomst voor het op de markt brengen van een innovatieve anticonceptiepil

Gedeon Richter Plc. en Pantarhei Bioscience BV maken vandaag bekend dat zij een licentieovereenkomst zijn aangegaan om Pantarhei’s nieuwe anticonceptiepil ARC (“Androgen Restored Contraception”) op de markt te brengen. Deze pil bevat 30 microgram ethinylestradiol (EE), 150 microgram levonorgestrel (LNG) en 50 mg dehydroepiandrosterone (DHEA). Voor dit product is het fase II klinische geneesmiddelenonderzoek succesvol afgerond. Het is nu gereed voor de laatste klinische studies om goedkeuring voor toelating tot de markt te verkrijgen. De overeenkomst is gesloten voor commercialisering in Europa, Rusland, Latijns-Amerika en Australië.

Read more:Persbericht Gedeon Richter – Pantarhei 4 februari 2019

Yvette Zimmerman new CEO Pantarhei Bioscience: “We find safe and effective new treatments using existing human molecules.”

Pantarhei Bioscience, the Dutch biopharmaceutical company, is pleased to announce the appointment of Yvette Zimmerman as Chief Executive Officer (CEO), with effect from January 2019. The founder of Pantarhei Herjan Coelingh Bennink speaks proudly about his successor: “Yvette is a very experienced drug developer and driven by what is really important for people and scientifically sound.”

During the 18 years of its existence, Pantarhei has filed more than 220 patents. Initially Pantarhei developed new medicines for Women’s Health. Following the foundation of the subsidiary company Pantarhei Oncology in 2014, the focus has been redirected to new treatment concepts for endocrine cancer, especially breast and prostate cancer.

Read more: Press Release New CEO Pantarhei Bioscience

Yvette Zimmerman nieuwe CEO Pantarhei Bioscience: “Wij ontdekken veilige en effectieve nieuwe geneesmiddelen op basis van bestaande menselijke moleculen.”

Het Nederlandse biofarmaceutische bedrijf Pantarhei Bioscience heeft met ingang van januari 2019 haar Chief Operating Officer (COO) Yvette Zimmerman benoemd tot Chief Executive Officer (CEO). De oprichter en voormalig CEO van Pantarhei, Herjan Coelingh Bennink, is trots op zijn opvolgster: “Yvette is een zeer ervaren ontwikkelaar van nieuwe geneesmiddelen, gemotiveerd door wat echt belangrijk is voor zieke mensen en wat wetenschappelijk vernieuwend is.”

Pantarhei bestaat nu 18 jaar en heeft in die tijd meer dan 220 patenten ingediend. Oorspronkelijk was Pantarhei gericht op het ontwikkelen van nieuwe geneesmiddelen op het gebied van Women’s Health. Sinds de oprichting van het dochterbedrijf Pantarhei Oncology in 2014, is de focus verlegd naar nieuwe hormonale behandelingen van kanker, met name borst- en prostaatkanker.

Lees verder: Persbericht Nieuwe CEO Pantarhei Bioscience

Zwangerschapshormoon Estetrol effectief bij behandeling van borstkanker

Pantarhei Oncology rapporteert positieve resultaten van de behandeling van borstkanker met het zwangerschapshormoon Estetrol.

Persbericht Pantarhei Oncology 6 december 2018

Fetal estrogen Estetrol effective for breast cancer treatment

Pantarhei Oncology announces favorable efficacy results of the fetal estrogen Estetrol in women with advanced breast cancer.

Press release Pantarhei Oncology December 6 2018

16th World congress on Menopause, June 6-9, 2018, Vancouver, Canada

On Friday June 8, 2018, the CSO of Pantarhei Carole Verhoeven lectured on the treatment of breast cancer with the fetal estrogen estetrol in a scientific symposium entitled ‘Estrogens and breast cancer’. The other lecture (A lesson in contracts. What can we learn from the discrepant breast cancer findings in the WHI?) was presented by Bob Langer. The symposium was chaired by Wulf Utian.

For more information, please read the abstract: Abstract IMS Treatment of breast cancer with the fetal estrogen estetrol.

 

 

First patient randomized in the PCombi study with Estetrol in patients with prostate cancer.

On 3 May 2018 the first patient has been randomized in the phase IIA clinical study assessing efficacy and safety of the fetal estrogen estetrol (E4) in prostate cancer patients. The study is a double blind, randomised, placebo-controlled multi-center study in prostate cancer patients treated with an LHRH agonist. In total 60 patients will be enrolled at eight centers in the Netherlands.

The main objectives of this study are to evaluate the additional effect of E4 on testosterone (T) suppression (total T as well as free T) by the LHRH agonist as well as the prevention and treatment of hypoestrogenic side effects due to the concomitant suppression of estrogens.

 

 

ISGE, March 7-10, 2018, Florence, Italy

On March 8, 2018 Pantarhei Bioscience participated in a scientific symposium entitled Estetrol and Breast Cancer. The lectures were presented by Richard J. Santen (Estetrol in animal in vivo studies), Risto Erkkola (Estetrol in ex vivo explant cultures of human breast cancer tissue) and Herjan Coelingh Bennink (Estetrol treatment of advanced breast cancer). The symposium was chaired by Ludwig Kiesel and Herjan Coelingh Bennink.

 

25th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) November 30- December 2, 2017, Vienna, Austria

On Friday December 1, 2017, the CEO of Pantarhei Herjan Coelingh Bennink lectured during the session: Breast cancer risk from hormonal treatment.

The title of the lecture qualified by the organisers as countercurrent was: “Estrogens protect against breast cancer and can be used in selected cases for the treatment of breast cancer”.

For more information please read the abstract: Abstract COGI Estrogens and Breast Cancer